Articles

An end-of-week review of retina news and stories from May 13 to May 20.

This week in retina: May 13-May 19

As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.

MacuLogix crosses threshold of 1 million dark adaption tests

Videos

EyePoint Pharmaceuticals hopes to usher in a new paradigm of retinal eye disease treatments with their candidate EYP-190.

EYP-1901 introduces treat-to-maintain paradigm for anti-VEGF therapy

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

Cell therapy trial may lead to treatment for dry AMD, geographic atrophy

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.

Tissue preservation should be considered as endpoint for geographic atrophy therapies

The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.

AAO applauds Congress for passage of key milestone for Improving Seniors' Timely Access to Care Act of 2021

Apellis revealed 18-month data for their investigational C3 therapy pegcetacoplan, unveiling continuous lesion growth reduction in eyes with geographic atrophy with monthly and every-other-month injections.

DERBY and OAKS: 18-month data shows continuous reduction in foveal, extrafoveal lesion growth in eyes with GA

Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.

Investigating the efficacy of targeting the Ang/Tie2 pathway with faricimab

In a patient survey, 66% of respondents said AI plays a large role in their diagnosis and treatment and thought it was important.

Patients recognize role of artificial intelligence in diagnosis, treatment

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

Investigating the efficacy of targeting the Ang/Tie2 pathway with faricimab

Patients recognize role of artificial intelligence in diagnosis, treatment

Amblyopia affects binocular vision, research suggests